MedPath

To Evaluate Efficacy and Safety of Norethisterone CR Tablet Versus Medroxyprogesterone Acetate Tablet for the treatment of Women with Dysfunctional Uterine Bleeding due to Hormonal Imbalance.

Phase 3
Conditions
Health Condition 1: null- Women who Diagnosed with Dysfunctional uterine bleeding due to hormonal imbalance
Registration Number
CTRI/2017/02/007931
Lead Sponsor
Synokem Pharmaceuticals Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
188
Inclusion Criteria

1. Age â?? Women between 25 - 45 years.

2. Actively bleeding female patients withDysfunctional Uterine Bleeding

due to hormonal imbalance in the reproductive age group.

3. Patients willing to give written informed consent.

Exclusion Criteria

1. Patients who have suffered a myocardial infarction, stroke, or life

threatening arrhythmia (or unstable angina) within the last 6 months.

2. Patients with uncontrolled (blood sugar levels specified above) or

complicated diabetics including diabetic retinopathy, diabetic neuropathy

or diabetic nephropathy)

3. Patients with bleeding disorders and patients with active peptic ulceration.

4. Patients with multiple myeloma, leukemia, lymphoma, agammaglobinaemia.

5. Patients with spinal cord injury.

6. Patients with any major psychiatric disorders (including Schizophrenia or

depression) not well controlled with treatment.

7. Significant history of presence of hematological, gastrointestinal, hepatic

or renal disease.

8. Patients with clinically significant abnormal LFT & RFT Values.

9. History of non- compliance to medical regimens or those patients

unwilling to comply with the study protocol.

10. Pregnant or breast-feeding women.

11. Patients with epilepsy, high blood pressure, or asthma.

12. Patients with liver or kidney problems.

13. Patients with pulmonary embolism & deep vein thrombosis.

14. Patients diagnosed with jaundice, severe itching, or a skin condition

called pemphigoid gestationis during a pregnancy.

15. Patients taking other medicines, including those available to buy without

a prescription, herbal and complementary medicines.

16. Patient allergic to any medicine.

17. Patients with hardness or lumps in the breasts.

18. Patients with family history of breast cancer.

19. Patients with intra uterine contraceptive devices.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the efficacy of Norethisterone versusMedroxyprogesterone AcetateTablets in <br/ ><br>women with Dysfunctional Uterine Bleeding due to hormonal imbalance.Timepoint: Day 1, On 28th day of 1st menstruation from screening,On 28th day of 2nd menstruation from screening, On 28th day of 3rd menstruation from screening
Secondary Outcome Measures
NameTimeMethod
To compare the safety and tolerability of Norethisterone versusMedroxyprogesterone <br/ ><br>AcetateTablets in women with Dysfunctional Uterine Bleeding due to hormonal imbalance.Timepoint: Day 1, On 28th day of 1st menstruation from screening,On 28th day of 2nd menstruation from screening, On 28th day of 3rd menstruation from screening
© Copyright 2025. All Rights Reserved by MedPath